

Plan Update

Notification Date: 06/02/2023

To: All Providers
From: MDwise Pharmacy Team
Subject: IHCP Transition to SUPDL
Effective Date: July 5, 2023

Summary

Please be advised that the Indiana Health Coverage Programs (IHCP) is transitioning to a Statewide Uniform Preferred Drug List (SUPDL) for the Fee-For-Service (FFS) and managed care entities (MCEs). Beginning July 5, 2023, all MCEs will adopt the FFS preferred drug list (PDL), maintaining the same preferred and nonpreferred drug status, clinical criteria requirements, and format for prior authorization (PA) submission as the FFS program.

The SUPDL will include products in the drug classes listed on the FFS PDL. Patients utilizing nonpreferred products will need to be transitioned to preferred products within 90 days of the July 5, 2023, implementation date. If you feel it is medically necessary for your patient(s) to remain on a nonpreferred product, you will need to submit a prior authorization (PA) request.

Impact

PA requests for MDwise Healthy Indiana Plan (HIP) or Hoosier Healthwise enrollees should be sent to the MDwise Pharmacy Benefit Manager (PBM), MedImpact. You may contact the MedImpact PA Department by phone at (800) 788-2949, or PA requests may be faxed to (858) 790-7100.

We appreciate your efforts to ensure our IHCP members maintain access to their medications through the SUPDL transition and thereafter by selecting products on the SUPDL whenever possible. Thank you for the work you do caring for our members.

Action

If you have any questions about the SUPDL as it pertains to MDwise Healthy Indiana Plan (HIP) and Hoosier Healthwise members, please call the MDwise Customer Contact Center toll-free at (800) 356-1204.

The Indiana Family & Social Services Administration (FSSA) has also provided list of [frequently asked questions](#) on the SUPDL.

RXP0027 (05/23)